NAS:RXRX (USA)
Â
Class A
$
8.34
+0.51 (+6.52%)
09:08 PM EST
Warning! GuruFocus detected
1 Severe warning sign
with RXRX.
Try a 7-Day Free Trial
to check it out.
Business Description
Recursion Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75629V1044
Share Class Description:
RXRX: Class ADescription
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.73 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.8 | |||||
| Beneish M-Score | -3.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 91.6 | |||||
| 3-Year EBITDA Growth Rate | -26.8 | |||||
| 3-Year EPS without NRI Growth Rate | -27.6 | |||||
| 3-Year FCF Growth Rate | -46 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.31 | |||||
| 9-Day RSI | 52.96 | |||||
| 14-Day RSI | 46.34 | |||||
| 6-1 Month Momentum % | 84.09 | |||||
| 12-1 Month Momentum % | 95.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | |||||
| Quick Ratio | 4.7 | |||||
| Cash Ratio | 4.2 | |||||
| Days Payable | 32.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.5 | |||||
| Shareholder Yield % | 0.01 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 2.94 | |||||
| Operating Margin % | -797.84 | |||||
| Net Margin % | -747.71 | |||||
| FCF Margin % | -684.5 | |||||
| ROE % | -71.74 | |||||
| ROA % | -50.01 | |||||
| ROIC % | -131.24 | |||||
| ROC (Joel Greenblatt) % | -271.39 | |||||
| ROCE % | -59.58 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 39.18 | |||||
| PB Ratio | 4.21 | |||||
| Price-to-Tangible-Book | 5.21 | |||||
| EV-to-EBIT | -4.56 | |||||
| EV-to-EBITDA | -4.92 | |||||
| EV-to-Revenue | 34.51 | |||||
| EV-to-FCF | -5.04 | |||||
| Price-to-Net-Current-Asset-Value | 7.87 | |||||
| Price-to-Net-Cash | 9.7 | |||||
| Earnings Yield (Greenblatt) % | -21.93 | |||||
| FCF Yield % | -15.18 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers